Prolia Or Ranmark Market Report 2026

Prolia Or Ranmark Market Overview

• The Prolia Or Ranmark market growth in the historic period has been driven by increasing prevalence of osteoporosis, rising incidence of bone metastases • Market expansion is supported by increasing demand for personalized bone therapies, rising investments in biologics manufacturing • Growth Driver: Impact of Growing Incidence of Bone Cancer On The Market • Market Trend: Adoption Of Denosumab Biosimilars To Improve Patient Access And Reduce Treatment Costs • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Prolia Or Ranmark Market?

Prolia or ranmark refers to a prescription medication containing denosumab, which inhibits RANKL to reduce bone resorption. By binding to RANKL, it prevents its interaction with osteoclasts, the cells responsible for bone breakdown. This increases bone density, strengthens bones, and lowers fracture risk. It is used to treat osteoporosis and bone metastases in cancer patients. The main indications in the prolia or ranmark market are osteoporosis and bone metastasis. Osteoporosis is a medical condition characterized by weakened bones, increasing the risk of fractures, particularly in older adults and postmenopausal women. It is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by a range of end users such as hospitals, specialty clinics, homecare providers, and ambulatory surgical centers.

What Is The Prolia Or Ranmark Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for personalized bone therapies, rising investments in biologics manufacturing, growing focus on fracture prevention strategies, expansion of specialty clinic treatment models, increasing adoption of long-acting injectable drugs. Major trends in the forecast period include increasing adoption of targeted monoclonal antibody therapies, rising focus on bone density preservation treatments, growing use of injectable osteoporosis drugs, expansion of long-term osteoporosis management protocols, enhanced monitoring of treatment adherence.

What Is The Driver Of The Prolia Or Ranmark Market?

The growing incidence of bone cancer is expected to propel the growth of the prolia or ranmark market going forward. Bone cancer refers to a type of cancer that begins in the cells of the bones, and it can either be primary, originating in the bone itself, or secondary, spreading from other parts of the body. The growing incidence of bone cancer is attributed to factors such as genetic predisposition, exposure to radiation, and certain inherited conditions. Prolia or Xgeva (denosumab) assists in bone cancer by inhibiting the activity of osteoclasts, which are responsible for bone resorption, thereby reducing the risk of bone fractures and slowing down the progression of bone metastases in cancer patients. For instance, in 2023, according to the American Cancer Society, a US-based professional organization, the estimated number of new cancer cases for bones and joints increased to 3,970, up from 3,910 in 2022. Therefore, the growing incidence of bone cancer is driving the growth of the prolia or ranmark industry.

Key Players In The Global Prolia Or Ranmark Market

Major companies operating in the prolia or ranmark market are Amgen Inc., Daiichi Sankyo Co. Ltd.

Global Prolia Or Ranmark Market Trends and Insights

Major companies are operating in the prolia or ranmark market, focusing on developing technological advancements such as interchangeable denosumab biosimilars to enhance treatment accessibility, reduce therapy costs, and maintain comparable safety and efficacy to the reference biologic. An interchangeable denosumab biosimilar is a fully human monoclonal IgG2 antibody that binds RANKL, inhibiting osteoclast-mediated bone resorption, while being formulated identically to Prolia, allowing substitution at the pharmacy level. For instance, in March 2024, Sandoz, a Switzerland-based biosimilars company, launched Jubbonti (denosumab-bbdz), an FDA-approved interchangeable biosimilar to Prolia. The product provides the same indications and dosing regimen as Prolia but is priced approximately 14% lower, improving patient access while preserving clinical efficacy and safety.

What Are Latest Mergers And Acquisitions In The Prolia Or Ranmark Market?

In June 2024, Alvotech, a Luxembourg-based biotechnology company, expanded their strategic collaboration with Stada Arzneimittel AG to include a new biosimilar, AVT03, which is a proposed treatment for conditions such as osteoporosis and bone cancer, referencing Amgen's prolia and Xgeva (denosumab). Stada Arzneimittel AG is a Germany-based pharmaceutical company that provides biosimilar products.

What Defines the Prolia Or Ranmark Market?

The prolia or ranmark market consists of sales of prolia subcutaneous injections, 60 mg and 120 mg and ranmark subcutaneous injection 120 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prolia Or Ranmark Market Report 2026?

The prolia or ranmark market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prolia or ranmark industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.